학술논문
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Document Type
Article
Author
Hurvitz, S.A.; Hegg, R.; Chung, W.-P.; Im, S.-A.; Jacot, W.; Ganju, V.; Chiu, J.W.Y.; Xu, B.; Hamilton, E.; Madhusudan, S.; Iwata, H.; Altintas, S.; Henning, J.-W.; Curigliano, G.; Perez-Garcia, J.M.; Cortés, J.; Kim, S.-B.; Petry, V.; Huang, C.-S.; Li, W.; Frenel, J.-S.; Antolin, S.; Yeo, W.; Bianchini, G.; Loi, S.; Tsurutani, J.; Egorov, A.; Liu, Y.; Cathcart, J.; Ashfaque, S.
Source
In: The Lancet . (The Lancet, 14 January 2023, 401(10371):105-117)
Subject
Language
English
ISSN
1474547X
01406736
01406736